QUEBEC CITY,
April 2, 2013 /PRNewswire/ -
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF), today announced that
the Company's stock is now trading on OTCQX International under the
symbol "DGCRF". OTCQX is the best U.S. OTC marketplace, providing
an opportunity to significantly broaden and enhance DiagnoCure's
access and exposure within the U.S. market. The OTCQX marketplace
has earned an exemplary reputation for providing U.S. investors
with improved liquidity, transparency, superior information, and
easy access through their U.S. regulated broker dealers. It is also
recognized within the industry for maintaining rigid quotation
standards for companies that trade there. Investors can find
current financial disclosures and Real-Time Level 2 quotes for
DiagnoCure on www.otcmarkets.com.
In addition, DiagnoCure announced today
that its company information would be made available
via Standard & Poor's Corporation Records Listing Program.
As part of the program, a full description of DiagnoCure will be
published in the Daily News Section of Standard & Poors'
Corporation Records, a recognized securities manual for secondary
trading in up to 38 states under the Blue Sky Laws. Standard &
Poor's Corporation Records is available in print, CD-ROM, and via
the web at www.netadvantage.standardandpoors.com as well as through
numerous electronic vendors. The company information about
DiagnoCure to be made available through this program includes an
in-depth description of the DiagnoCure's business operations, share
price, dividend history, shares outstanding, company financial
position, earnings, and full income statement and balance
sheet.
Canaccord Genuity will be the market maker of
DiagnoCure's stock. Canaccord Genuity is a global, full-service
investment bank focused on growth companies and is one of the
largest market maker in the United
States.
Dorsey & Whitney LLP will serve as
DiagnoCure's Principal American Liaison ("PAL") on OTCQX,
responsible for providing guidance on OTCQX requirements and U.S.
securities laws.
"Trading on OTCQX International will provide
enhanced access to U.S. investors and the ability for DiagnoCure to
diversify its shareholder base," said Chantal Miklosi, Chief Financial Officer of
DiagnoCure. "We believe that trading on the OTCQX marketplace is in
the best interest of shareholders and will enable the Company to
enhance the market liquidity of DiagnoCure shares."
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life
sciences corporation that develops and commercializes high-value
cancer diagnostic tests that increase clinician and patient
confidence in making critical treatment decisions. In 2008, the
Corporation launched a colorectal cancer staging test through its
U.S. CLIA laboratory. PrevistageTM GCC is currently
available for licensing. The Corporation has granted a worldwide
exclusive license to Gen-Probe, now a wholly-owned subsidiary of
Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the
development and commercialization of a prostate cancer test using
PCA3, DiagnoCure's proprietary molecular biomarker. Hologic
Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and
the United States. For more
information, visit www.diagnocure.com.
Forward‐looking statements
This release contains "forward‐looking
statements," within the meaning of applicable United States and Canadian securities laws,
that involve known and unknown risks, uncertainties and assumptions
that may cause actual results to differ materially from those
expected. By their very nature, forward‐looking statements are
based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond
DiagnoCure's control. As a result, investors are cautioned not to
place undue reliance on these forward‐looking statements. Such
forward-looking statements include the outcome of research and
development projects, clinical studies, future revenues, the
benefits of being quoted on the OTCQX and the improved liquidity of
the Company's shares when traded on the OTCQX and are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading
"Risk Factors". DiagnoCure undertakes no obligation to publicly
update or revise any forward‐looking statements contained herein
unless required by the applicable securities laws and
regulations.
SOURCE DiagnoCure inc.
